However, the dark side of Nrf2 is that it also contributes to chemo- and radio-resistance of human cancers [15–17], since activation of the Nrf2-Keap1 pathway by anticancer therapeutics increases the intracellular antioxidant capacity and therefore not only protects cancer cells but may also accelerate their proliferation. Here, KEAP1 is linked to cancer.